AstraZeneca
AstraZeneca invests £300 million in UK in boost for Starmer
The investment includes a new building at the British drugmaker’s headquarters in Cambridge
AstraZeneca beats sales and profit expectations on cancer drug demand
Core earnings for the three months ended March rise to US$2.58 per share, while total revenue jumps 8% to US$15.3 billion
AstraZeneca forecasts growth in 2026 as it builds drug pipeline
Its chief executive officer Pascal Soriot has a target of US$80 billion in annual sales by 2030
AstraZeneca strikes deal for up to US$18.5 billion to license weight-loss drugs from China's CSPC
The deal builds on existing collaboration between the companies in areas such as artificial intelligence
Walmart to join Nasdaq 100 on Jan 20 as AstraZeneca exits
The retailer has recently increased its use of AI across internal operations
AstraZeneca beats third-quarter expectations, maintains outlook
The firm will also list its shares on the NYSE to gain access to a deeper capital pool
AstraZeneca quarterly net profit jumps on record US growth
Profit after tax rose to US$2.45 billion in the three months to the end of June
AstraZeneca vows to spend US$50 billion on US manufacturing, development
President Donald Trump has proposed various timelines for tariffs on pharmaceuticals, most recently floating duties that would be imposed as soon as Aug 1
AstraZeneca seeks to move past China probe with Beijing R&D hub
The new R&D centre represents CEO Pascal Soriot doubling down on a key market in which his company has already invested heavily
AstraZeneca invests US$2.5 billion in Beijing, undeterred by probe
The hub will focus on early-stage research and include an artificial intelligence lab
